Clinical Trial Update: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH [Phase 3]

View source ↗

Summary

Phase 3 study evaluating denifanstat for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Metabolic Dysfunction-associated Steatotic Liver Disease

Drugs mentioned

• Denifanstat (denifanstat)

Snippet

Sponsor: Sagimet Biosciences Inc. | Conditions: MASLD, MASH | Phase 3 | Status: WITHDRAWN